Medtronic Announced Evolut Tavr Platform Met Both Co-primary Endpoints Of Clinical Non-inferiority And Hemodynamic Superiority At One Year
Portfolio Pulse from Charles Gross
Medtronic announced that its Evolut TAVR platform met both co-primary endpoints of clinical non-inferiority and hemodynamic superiority at one year in the largest head-to-head randomized control TAVR trial, demonstrating non-inferior clinical outcomes and superior valve performance compared to Sapien.
April 07, 2024 | 2:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Medtronic's Evolut TAVR platform demonstrated non-inferior clinical outcomes and superior valve performance compared to Sapien, potentially boosting its market share and revenue in the TAVR segment.
The positive trial results for Medtronic's Evolut TAVR platform indicate a competitive advantage over Sapien, likely leading to increased adoption and sales. This could positively impact Medtronic's stock price in the short term as investors react to the potential for increased market share and revenue in the TAVR segment.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90